[FW Radar] Sim & Cure wants to focus on medical imaging to treat patients

by bold-lichterman

Created in 2014 by Vincent Costalat and Mathieu Sanchez, Sim & Cure develops software to secure endovascular treatment of cerebral aneurysms.

More details with Mathieu Sanchez, co-founder and CEO of Sim & Cure.

FrenchWeb: What needs does your service meet?

Mathieu Sanchez, co-founder and CEO of Sim & Cure: Sim & Cure develops and markets software solutions to secure endovascular treatment of cerebral aneurysms. Brain aneurysm is one of the main causes of stroke. This pathology is present in 1 in 50 people and a rupture occurs every 18 minutes in the world. In the context of endovascular treatment (minimally invasive surgery), there is about 20% failure to insert devices intended to treat the aneurysm.

What’s your value proposition?

The objective of our software is to improve patient care by securing the therapeutic planning of the neuroradiologist. From medical imaging, patient-specific simulations are performed to define the optimal position and size of the device to treat each patient and thus reduce the rate of insertion failure from 20% to less than 5%.

Who are the users of your solutions?

The end users of the software are the neuroradiologists who perform the endovascular treatment. They are looking for a way to better understand the new generations of medical devices (DMI). These IMDs allow a very effective treatment of the aneurysm when they are well controlled. The “historical” practice of neuroradiologists is to perform measurements on the patient’s 2D medical imaging to choose the position and size of the DMI. This method leads to a bad choice in 20% of cases. Sim & Size allows them to visualize in 3D, in the vascular tree of the patient, the position and the shape that the DMI will take once released in vivo and therefore greatly reduce the failure rate.

What is your development plan?

The software is in the process of CE marking and should be deployed in Europe at the end of 2017.

We are also starting the development of our second product which will aim to help design future generations of DMI. The goal is to be present from design to installation of the DMI.

What are your challenges?

In 2017, our offer will be deployed in the Europe zone and then in 2018 in the US zone. Our mid-term objective is to be the market leader in brain simulation and to become a standard in the treatment of brain aneurysm.

To complete this project, the team will reach 12 collaborators by the end of the year and we plan to open an office in the USA in 2018.

Who are your competitors?

Our competitors are the manufacturers of medical imaging consoles (Philips, Siemens, GE) who offer therapeutic planning assistance tools in their respective workstations. There is also a Spanish start-up Galgo Medical which offers a simulation tool for Flowdiverter type stents.

Our main advantage is to be able to simulate very precisely and quickly all the IMDs that can treat the cerebral aneurysm in order to be able to give neuroradiologists a global vision of the “field of possibilities” to treat their patient.

Founders: Vincent Costalat and Mathieu Sanchez

Creation date : August 19, 2014

Fundraising : 300,000 euros in December 2015 with IT Translation

Seat : Paris

Read also: Hellocare wants to transpose the medical consultation on an application and in video

1605400948 497 Start up scientifiques biotechs 1 FrenchWebfr